Cyclin-dependent kinases (CDKs) regulate cell-cycle progression and have long been investigated as therapeutic targets in oncology. The clinical success of selective CDK4/6 inhibitors in breast cancer established the therapeutic value of CDK inhibition. However, despite more than a decade of research, resistance, off-target effects, and limited efficacy in other tumor types have restricted their broader use as antitumor therapies.
CDK Inhibitors in Oncology: Emerging Opportunities and Translational Models for Drug Development
calendar_today
November 4, 2026
person
david.vallerand@crownbio.com (David Vallerand, PhD)
domain
crownbio